We are live on ! Find out more
VMI

VHCP Management II Portfolio holdings

AUM $379M
1-Year Est. Return 421.62%
This Fund
S&P 500
This Quarter Est. Return
+0.23%
1 Year Est. Return
+421.62%
3 Year Est. Return
+2,333.62%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$122M
AUM Growth
–
Cap. Flow
+$138M
Cap. Flow %
113.09%
Top 10 Hldgs %
86.99%
Holding
15
New
15
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
PDSB icon
PDS Biotechnology
PDSB
+$31.2M
2
RGNX icon
Regenxbio
RGNX
+$20.5M
3
ASND icon
Ascendis Pharma A/S
ASND
+$12.6M
4
CTMX icon
CytomX Therapeutics
CTMX
+$9.54M
5
ARCT icon
Arcturus Therapeutics
ARCT
+$7.27M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 85.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PDSB icon
1
PDS Biotechnology
PDSB
$39.2M
$22.2M 18.21%
+96,679
New +$31.2M
RGNX icon
2
Regenxbio
RGNX
$656M
$15.9M 13.04%
+1,030,954
New +$20.5M
ASND icon
3
Ascendis Pharma A/S
ASND
$16.6B
$13.2M 10.85%
+721,152
New +$12.6M
CTMX icon
4
CytomX Therapeutics
CTMX
$725M
$11.6M 9.56%
+603,031
New +$9.54M
ARCT icon
5
Arcturus Therapeutics
ARCT
$165M
$7.1M 5.83%
+161,500
New +$7.27M
CHRS icon
6
Coherus Oncology
CHRS
$221M
$5.95M 4.89%
+259,259
New +$6.67M
LPCN icon
7
Lipocine
LPCN
$18.1M
$5.43M 4.46%
+24,706
New +$5.18M
AKTX
8
Akari Therapeutics
AKTX
$16.3M
$5.36M 4.4%
+462
New +$6.86M
ORKA
9
Oruka Therapeutics
ORKA
$5.55B
$5.02M 4.12%
+4,995
New +$5.66M
GBT
10
DELISTED
Global Blood Therapeutics, Inc.
GBT
$4.58M 3.76%
+141,611
New +$6.13M
ADVM
11
DELISTED
Adverum Biotechnologies
ADVM
$2.67M 2.19%
+28,000
New +$2.46M
SRRA
12
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$2.63M 2.16%
+4,375
New +$2.96M
STML
13
DELISTED
Stemline Therapeutics, Inc.
STML
$1.99M 1.64%
+315,980
New +$2.56M

Similar funds

ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
PI
PHH Investments Addison, Texas $378M AUM 19.74% 1-Year Est. Return
SC
Southside Capital Miami Beach, Florida $382M AUM 30.29% 1-Year Est. Return
FFSOTS
Fiduciary Financial Services of The Southwest Dallas, Texas $382M AUM 25.98% 1-Year Est. Return
PC
Passport Capital San Francisco, California $394M AUM 50.67% 1-Year Est. Return
WC
Whitnell & Co Oak Brook, Illinois $326M AUM 25.97% 1-Year Est. Return
VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
LB
Landmark Bank Columbia, Missouri $444M AUM 30.12% 1-Year Est. Return

VHCP Management II's Q4 2015 Portfolio in Review

Q4 2015 is the first quarter with a 13F filing on record for VHCP Management II, which disclosed 15 positions worth $122M. Its ten largest holdings account for 87% of the portfolio.

Its largest position is PDS Biotechnology: 96,679 shares worth $22.2M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets.

  • VHCP Management II's largest Q4 2015 buy was PDS Biotechnology: 96,679 shares worth $22.2M.
  • VHCP Management II's ten largest holdings make up 87% of its $122M portfolio in Q4 2015.
  • VHCP Management II disclosed 15 positions in Q4 2015, its first 13F filing on record.

Based on VHCP Management II's 13F filing for Q4 2015, filed 12 Feb 2016.